{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicydxvd7wugmogzvo5t24katak3ibbkuhocmizg7rqf64llpeuzce",
    "uri": "at://did:plc:7ltlvigjik37fxbx2bat4p22/app.bsky.feed.post/3mp3vulmmbo42"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiaterdbnzl5rqr4owyr2mombapdqih4mtia2g4oiiycg6wizzr6yq"
    },
    "mimeType": "image/jpeg",
    "size": 122813
  },
  "path": "/disease/obesity/daily-weight-loss-pill-trials/",
  "publishedAt": "2026-06-25T07:19:30.000Z",
  "site": "https://refractor.io",
  "tags": [
    "Continue Reading",
    "Obesity",
    "Illnesses and conditions",
    "Body and Mind",
    "GLP-1 receptor agonists",
    "Weight Loss",
    "clinical trials",
    "Fat cells",
    "peptide",
    "Pharmaceuticals",
    "BioLogic",
    "Experimental"
  ],
  "textContent": "A once-a-day, low-impact oral GLP-1 pill known as CX11 has passed its efficacy test on US patients to advance to the first North American Phase 3 trial. It's already cleared its first Phase 3 study in China.\n\nContinue Reading\n\n**Category:** Obesity, Illnesses and conditions, Body and Mind\n\n**Tags:** GLP-1 receptor agonists, Weight Loss, clinical trials, Fat cells, peptide, Pharmaceuticals, BioLogic, Experimental, Obesity",
  "title": "Daily weight-loss pill with low side effects advances toward US sale"
}